Ramin Ebrahimi
Nuclear Cardiology · Los Angeles, CANPI 1992816631
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $423,321 of the $542,227 with a category attached, or 78.1%. Novo Nordisk accounts for 81.7% of it on its own, with 14 other manufacturers making up the rest.
Across 286 payments — averaging $1895.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$443K
- Amarin Pharma, Inc.$34K
- Pfizer$21K
- Johnson & Johnson$16K
- Sanofi-aventis U.S. LLC$6K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$6K
- plus $16K from 9 others
Across 17 payments — averaging $3072.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$43K
- Pfizer$7K
- Boehringer Ingelheim International GmbH$2K
What the payments were for
- Consulting fees$69,74613%
- Speaking & faculty fees$423,32178%
- Travel & lodging$40,1897%
- Food & beverage$8,9332%
- Education$370%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 199 | $443,117 |
| Amarin Pharma, Inc. | 38 | $34,021 |
| Pfizer | 5 | $21,403 |
| Johnson & Johnson | 11 | $16,209 |
| Sanofi-aventis U.S. LLC | 1 | $6,188 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $5,755 |
| Novartis | 2 | $5,234 |
| Chiesi USA, Inc. | 5 | $3,900 |
| Biotronik Inc. | 4 | $3,007 |
| E.r. Squibb & Sons, L.L.C. | 1 | $1,800 |
| Novo Nordisk AS | 7 | $1,154 |
| Penumbra, Inc. | 1 | $235 |
| Angiodynamics, Inc. | 2 | $145 |
| Shockwave Medical, Inc | 1 | $33 |
| Abbott | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few nuclear cardiology providers in Californiato place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 13 | $6,979 |
| VascepaIcosapent Ethyl | 12 | $4,885 |
Paid to pharmacies, not to this prescriber.
Other nuclear cardiology in Los Angeles
- Howard LewinLos Angeles$5K
- Teresa DanieleFresno$45K
- Christopher OhSalinas$17K
- Absalom HepnerMission Viejo$9K
- Victor GabrielianArcadia$4K
- Ankit RathodFresno$2K
- Arjun SharmaSacramento$1K
- Kusai AzizVisalia$326
- Thomas WattersSan Mateo$17
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.